B. Kramer

R. Hayes, B. Kramer, J. Weissfeld, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance.

B. Kramer, J. Minna, A. Gazdar, 1994, Lung cancer.

Simple Methods for Evaluating 4 Types of Biomarkers: Surrogate Endpoint, Prognostic, Predictive, and Cancer Screening

B. Kramer, S. Baker, 2020, Biomarker insights.

Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes

B. Kramer, S. Baker, 2015, Clinical trials.

Transforming Epidemiology for 21st Century Medicine and Public Health

J. Ioannidis, T. Sellers, G. Ginsburg, 2013, Cancer Epidemiology, Biomarkers & Prevention.

Potential role of tamoxifen in prevention of breast cancer.

B. Kramer, L. Ford, J. Karp, 1991, Journal of the National Cancer Institute.

Surrogate endpoint analysis: an exercise in extrapolation.

B. Kramer, S. Baker, 2013, Journal of the National Cancer Institute.

The risky reliance on small surrogate end point studies when planning a large prevention trial

B. Kramer, S. Baker, 2013, Journal of the Royal Statistical Society. Series A,.

Here's to Your Health

M. Glickman, B. Kramer, S. Baker, 2006 .

Overview of U.S. National Cancer Institute (USNCI) chemoprevention research.

B. Kramer, P. Greenwald, L. Ford, 1994, Acta oncologica.

Cancer Care Delivery Research: Building the Evidence Base to Support Practice Change in Community Oncology.

B. Kramer, A. Kaluzny, W. McCaskill-Stevens, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Estimating overdiagnosis in lung cancer screening--reply.

B. Kramer, P. Pinsky, E. Patz, 2014, JAMA Internal Medicine.

Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.

P. Prorok, R. Hayes, B. Kramer, 2007, American journal of epidemiology.

The role of increasing detection in the rising incidence of prostate cancer.

B A Miller, P C Albertsen, B. Kramer, 1995, JAMA.

The science of early detection.

B. Kramer, 2004, Urologic oncology.

Schedule‐dependent in vitro combination effects of methotrexate and 5‐fluorouracil in human tumor cell lines

B. Kramer, A. Gazdar, R. Perng, 1991, International journal of cancer.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

P. Prorok, B. Kramer, C. Berg, 2010, Clinical trials.

Cancer screening.

B. Kramer, O. Brawley, 2021, Hematology/oncology clinics of North America.

Focusing on overdiagnosis as a driver of too much medicine

Lisa M. Schwartz, B. Kramer, J. Brodersen, 2018, British Medical Journal.

Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study.

Peter C Gøtzsche, Steven Woloshin, David F Ransohoff, 2007, Archives of internal medicine.

Breast Cancer Screening

Joann G. Elmore, Barnett S. Kramer, J. Elmore, 2014 .

Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening

J. Gohagan, B. Kramer, E. Crawford, 2009, The Annals of Family Medicine.

The Mayo Lung Project lung cancer mortality findings are unlikely to be biased by a volunteer effect

B. Kramer, P. Marcus, R. Fontana, 2011, European Journal of Epidemiology.

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.

S. Steinberg, B. Kramer, A. Gazdar, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reported family history of cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

B. Kramer, S. Buys, D. Reding, 2003, American journal of epidemiology.

The National Lung Screening Trial: Results stratified by demographics, smoking history, and lung cancer histology

B. Kramer, T. Church, G. Izmirlian, 2013, Cancer.

Cancer screening campaigns--getting past uninformative persuasion.

Lisa M. Schwartz, B. Kramer, W. Black, 2012, The New England journal of medicine.

National Lung Screening Trial Findings by Age: Medicare-Eligible Versus Under-65 Population

B. Kramer, P. Pinsky, D. Gierada, 2014, Annals of Internal Medicine.

Validation: a critical step in bringing biomarkers to clinical fruition.

B. Kramer, S. Srivastava, 2017, Annals of epidemiology.

Is screening for prostate cancer the current gold standard?--"no".

J. Gohagan, P. Prorok, B. Kramer, 1997, European journal of cancer.

Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute.

P C Prorok, J. Gohagan, P. Prorok, 1994, The Journal of urology.

Reply to P.C. Walsh

B. Kramer, P. Schellhammer, M. Somerfield, 2009 .

Projecting the benefits and harms of mammography using statistical models: proof or proofiness?

J. Elmore, B. Kramer, 2015, Journal of the National Cancer Institute.

The prostate, lung, colorectal, and ovarian cancer screening trial of the national cancer institute

J. Gohagan, P. Prorok, R. Hayes, 1995 .

Relationship of demographic and clinical factors to free and total prostate-specific antigen.

J. Gohagan, R. Hayes, B. Kramer, 2001, Urology.

National Institutes of Health Consensus Development Conference Statement on Cervical Cancer

W. H. Hall, P. Grigsby, B. Kramer, 1997 .

Epidemiologic Signatures in Cancer.

B. Kramer, H. Welch, W. Black, 2019, The New England journal of medicine.

Analysis of the role of cancer prevention and control measures in reducing cancer mortality.

B. Kramer, C. Smart, K. Chu, 1991, Journal of the National Cancer Institute.

Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines.

S. Steinberg, B. Kramer, A. Gazdar, 1988, Journal of the National Cancer Institute.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence declinein the United States

E. Feuer, B. Kramer, J. Legler, 1998, Cancer Causes & Control.

Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.

J. Cuzick, B. Kramer, P. Brown, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dipyridamole mediated enhanced antiproliferative activity of 10‐ethyl‐10‐deazaaminopterin (10‐EDAM) against human lung cancer cell lines

B. Kramer, A. Gazdar, J. Mulshine, 1996, Journal of cellular biochemistry. Supplement.

Reply to J. Cabezas et al.

B. Kramer, A. Sabichi, M. Somerfield, 2016, Journal of Clinical Oncology.

Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

B. Kramer, A. Sabichi, M. Somerfield, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

5-Alpha-reductase inhibition and prostate cancer prevention.

B. Kramer, I. Thompson, L. Ford, 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

Principles of cancer screening: lessons from history and study design issues.

David F Ransohoff, Barnett S Kramer, B. Kramer, 2010, Seminars in oncology.

Trends and black/white differences in treatment for nonmetastatic prostate cancer.

B. Kramer, C. Klabunde, A. Potosky, 1998, Medical care.

Lead time and overdiagnosis.

P. Prorok, B. Kramer, S. Baker, 2014, Journal of the National Cancer Institute.

5‐α‐Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review

T. Wilt, R. MacDonald, B. Kramer, 2010, BJU international.

Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary.

T. Wilt, B. Kramer, P. Schellhammer, 2009, Journal of oncology practice.

Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

T. Wilt, B. Kramer, P. Schellhammer, 2009, The Journal of urology.

Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline

T. Wilt, B. Kramer, M. Somerfield, 2009 .

Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial

J. Gohagan, P. Prorok, B. Kramer, 2008, BJU international.

Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.

Sallie J. Weaver, B. Kramer, H. Ciolino, 2021, JNCI cancer spectrum.

American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

B. Kramer, A. Sabichi, M. Somerfield, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Special Feature — Biostatistics: Why Biotechnologists Should Care about Biostatistics

B. Kramer, S. Baker, 2006 .

Expanding horizons in breast and prostate cancer prevention and early detection. The 1992 Samuel C. Harvey Lecture.

B. Kramer, D. Weed, P. Greenwald, 1993, Journal of cancer education : the official journal of the American Association for Cancer Education.

Colorectal cancer prevention and fishful thinking.

B. Kramer, E. Richmond, A. Umar, 2015, Journal of the National Cancer Institute.

Statistics for weighing benefits and harms in a proposed genetic substudy of a randomized cancer prevention trial

B. Kramer, Stuart G. Baker, 2005 .

Evaluation of in vitro chemosensitivity using human lung cancer cell lines

B. Kramer, R. Kratzke, 1996, Journal of cellular biochemistry. Supplement.

Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial.

B. Kramer, J. Gockerman, R. Birch, 1986, Cancer treatment reports.

Phase II evaluation of acivicin in lung cancer: a Southeastern Cancer Study Group Trial.

B. Kramer, R. Johnson, R. Birch, 1986, Cancer treatment reports.

Cutaneous infarction. Manifestation of disseminated mucormycosis.

B. Kramer, R. Reddick, A. Levine, 1977, Archives of dermatology.

Cancer prevention and the American Society of Clinical Oncology.

B. Kramer, M. Somerfield, S. Lippman, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conceptualizing De-Implementation in Cancer Care Delivery.

David A. Chambers, B. Kramer, W. Norton, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Op-Ed Spiral computed tomography screening

B. Kramer, 2001 .

Cancer overdiagnosis: a challenge in the era of screening.

B. Kramer, S. Woloshin, B. Dunn, 2022, Journal of the National Cancer Center.

Predictive Value Tools as an Aid in Chemopreventive Agent Development.

B. Kramer, V. Steele, D. Ransohoff, 2013, Journal of the National Cancer Institute.

The randomized registry trial.

B. Kramer, S. Baker, K. Lindeman, 2014, New England Journal of Medicine.

A phase II study of continuous infusion 5‐fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma

B. Kramer, D. Venzon, J. Grem, 1993, Cancer.

Effect of adjuvant central iv hyperalimentation on the survival and response to treatment of patients with small cell lung cancer: a randomized trial.

B. Kramer, R. Makuch, G. Clamon, 1985, Cancer treatment reports.

A common standard for conflict of interest disclosure in addiction journals.

B. Kramer, J. Moreno, T. Babor, 2009, Addiction.

Role of serial microbiologic surveillance and clinical evaluation in the management of cancer patients with fever and granulocytopenia.

B. Kramer, P. Pizzo, R. Wesley, 1982, The American journal of medicine.

Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study

B. Kramer, J. D. Malone, R. Ramphal, 1992, Antimicrobial Agents and Chemotherapy.

Identifying genes that contribute most to good classification in microarrays

Stuart G. Baker, Barnett S. Kramer, B. Kramer, 2006, BMC Bioinformatics.

Challenges in Quantifying Overdiagnosis

P. Prorok, B. Kramer, S. Baker, 2017 .

National Children's Study: update in 2010.

B. Kramer, A. Guttmacher, S. Hirschfeld, 2011, The Mount Sinai journal of medicine, New York.

Serum folate and vitamin B12 levels in patients with small cell lung cancer

B. Kramer, G. Clamon, R. Feld, 1984, Cancer.

Short‐Term Outcome Among Patients With Leukemia and Lymphoma Admitted to a Medical Intensive Care Unit

B. Kramer, E. Harman, 1986, Southern medical journal.

Effects of intravenous hyperalimentation during treatment in patients with small-cell lung cancer.

B. Kramer, D. Pee, G. Clamon, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer chemotherapy associated symptomatic stomatitis. Role of herpes simplex virus (HSV)

B. Kramer, K. Rand, Alicia C. Johnson, 1982, Cancer.

Combination cytotoxic effects of cis-diamminedichloroplatinum(II) and 5-fluorouracil with and without leucovorin against human non-small cell lung cancer cell lines.

B. Kramer, A. Gazdar, R. Perng, 1993, Cancer research.

Biomarkers, subgroup evaluation, and clinical trial design.

B. Kramer, D. Sargent, M. Bonetti, 2012, Discover medicine.

Prostate cancer screening: current issues.

J. Gohagan, P. Prorok, B. Kramer, 1996, Cancer treatment and research.

"Screening for prostate cancer".

J. Gohagan, B. Kramer, P. Greenwald, 1994, American journal of preventive medicine.

Chemosensitivity patterns and expression of human multidrug resistance-associated MDR1 gene by human gastric and colorectal carcinoma cell lines.

B. Kramer, A. Gazdar, J. G. Park, 1990, Journal of the National Cancer Institute.

Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: a Southeastern Cancer Study Group Trial.

B. Kramer, L. Einhorn, A. Bartolucci, 1986, Cancer treatment reports.

5-a-Reductase inhibitors for prostate cancer chemoprevention: An updated Cochrane systematic review (BJU International (2010) 106:10 (1444-1451))

T. Wilt, R. MacDonald, B. Kramer, 2011 .

Design of the Prostate Cancer Prevention Trial (PCPT).

J. Crowley, B. Kramer, I. Thompson, 1995, Controlled clinical trials.

Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay.

S. Steinberg, B. Kramer, J. Minna, 1987, Cancer research.

New Models for Large Prospective Studies: Is There a Better Way?

Tim Peakman, Catherine A. McCarty, J. Michael Gaziano, 2012, American journal of epidemiology.

Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients.

B. Kramer, G. Samsa, A. Belani, 1987, The American journal of medicine.

Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial.

B. Kramer, B. Edwards, P. Pizzo, 1983, The Journal of pediatrics.

Early results of a comparative trial of ceftazidime versus cephalothin, carbenicillin and gentamicin in the treatment of febrile granulocytopenic patients.

B. Kramer, R. Ramphal, J. Shands, 1983, The Journal of antimicrobial chemotherapy.

Effect of Filtering Amphotericin B Infusions on the Incidence and Severity of Phlebitis and Selected Adverse Reactions

B. Kramer, K. Rand, V. Gotz, 1985, Drug intelligence & clinical pharmacy.

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identifying and Creating the Next Generation of Community-Based Cancer Prevention Studies: Summary of a National Cancer Institute Think Tank

B. Kramer, W. McCaskill-Stevens, L. Ford, 2016, Cancer Prevention Research.

Randomized Phase II Evaluation of Iproplatin (CHIP) and Carboplatin (CBDCA) in Lung Cancer: A Southeastern Cancer Study Group Trial

B. Kramer, R. Birch, P. Desimone, 1988, American journal of clinical oncology.

Population-based screening for cancer: hope and hype

L. Esserman, M. Eklund, B. Kramer, 2016, Nature Reviews Clinical Oncology.

Spontaneous regression of testicular seminoma: case report.

B. Kramer, I. Klimberg, Z. Wajsman, 1986, The Journal of urology.

An outlier theory of cancer curability. Tumor cell differentiation as a therapeutic goal.

B. Kramer, M. Levitt, E. Seifter, 1987, The American journal of medicine.

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.

S. Steinberg, B. Kramer, J. Grem, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enhancement of fluorinated pyrimidine‐induced cytotoxicity by leucovorin in human lung cancer cell lines

B. Kramer, A. Gazdar, R. Perng, 1990, International journal of cancer.

Lack of in vitro synergy between etoposide and cis-diamminedichloroplatinum(II).

S. Steinberg, B. Kramer, A. Gazdar, 1989, Cancer research.

Genetics of lung cancer: implications for early detection and prevention.

B. Kramer, S. Srivastava, 1995, Cancer treatment and research.

AACR White Paper: Shaping the Future of Cancer Prevention – A Roadmap for Advancing Science and Public Health

G. Colditz, B. Kramer, T. Rebbeck, 2018, Cancer Prevention Research.

Molecular and genetic targets in early detection.

B. Kramer, D. Henson, S. Srivastava, 1999, Current opinion in oncology.

Phase III, large-scale chemoprevention trials. Approach to chemoprevention clinical trials and phase III clinical trial of tamoxifen as a chemopreventive for breast cancer--the US National Cancer Institute experience.

B. Kramer, L. Ford, B. Dunn, 1998, Hematology/oncology clinics of North America.

Cancer overdiagnosis: a biological challenge and clinical dilemma

B. Kramer, A. D. De Marzo, A. Borowsky, 2019, Nature Reviews Cancer.

Design and endpoints of clinical trials in hepatocellular carcinoma.

Riccardo Lencioni, Barnett S Kramer, Jayant Talwalkar, 2008, Journal of the National Cancer Institute.

Cancer Overdiagnosis, Ramifications and Research Strategies

B. Kramer, B. Dunn, 2017 .

Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: a computer simulation of morphostats

B. Kramer, J. Potter, S. Baker, 2009, BMC Cancer.

Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy.

Mark P Purdue, Barnett S Kramer, John K Gohagan, 2012, The New England journal of medicine.

Paradoxes in carcinogenesis: New opportunities for research directions

Stuart G Baker, Barnett S Kramer, B. Kramer, 2007, BMC Cancer.

Treatment of Residual Disease in AML: Interim Analysis of a Southeastern Cancer Study Group Prospective Randomized Clinical Trial

B. Kramer, D. Shina, R. Weiner, 1986 .

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

B. Kramer, M. Khoury, K. Goddard, 2015, Journal of the National Cancer Institute.

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of injectable and oral paste formulations of ivermectin against gastrointestinal parasites in ponies.

B. Kramer, T. Klei, B. Torbert, 1982, American journal of veterinary research.

Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

B. Kramer, M. Kris, R. Schilsky, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment.

B. Kramer, P. Brown, J. Garber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized comparison between two ceftazidime-containing regimens and cephalothin-gentamicin-carbenicillin in febrile granulocytopenic cancer patients

B. Kramer, R. Ramphal, K. Rand, 1986, Antimicrobial Agents and Chemotherapy.

Granulocytopenic Cancer Patients

B. Kramer, R. Ramphal, K. Rand, 2022 .

Good for women, good for men, bad for people: Simpson's paradox and the importance of sex-specific analysis in observational studies.

S G Baker, B. Kramer, S. Baker, 2001, Journal of women's health & gender-based medicine.

The management of primary lymphoma of bone.

B. Kramer, W. Enneking, R. Marcus, 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Cancer Prevention: Lessons Learned and Future Directions.

B. Kramer, B. Dunn, 2016, Trends in cancer.

Chemoprevention : Using Drugs and Nutrients to Decrease Cancer Risk

B. Kramer, B. Dunn, 2016 .

Tobacco addiction: implications for treatment and cancer prevention.

B. Kramer, S. Hecht, J. Henningfield, 1997, Journal of the National Cancer Institute.

SPECIAL ARTICLE Tobacco Addiction: Implications for Treatment and Cancer Prevention

B. Kramer, S. Hecht, J. Henningfield, 1997 .

A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers

P C Prorok, P. Prorok, B. Kramer, 2010, Cancer.

Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

B. Kramer, P. Pinsky, 2015, Journal of the National Cancer Institute.

Prostate Cancer Screening - A Perspective on the Current State of the Evidence.

P. Prorok, B. Kramer, P. Pinsky, 2017, The New England journal of medicine.

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

J. Gohagan, P. Prorok, B. Kramer, 2005, Journal of the National Cancer Institute.

Systems biology and cancer: promises and perils.

Stuart G Baker, Barnett S Kramer, B. Kramer, 2011, Progress in biophysics and molecular biology.

Prophylaxis of fever and infection in adult cancer patients. A placebo‐controlled trial of oral trimethoprim‐sulfamethoxazole plus erythromycin

B. Kramer, K. Rand, P. Pizzo, 1984, Cancer.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

J. Gohagan, P. Prorok, B. Kramer, 2017, Cancer.

Clinical trial design and evidence-based outcomes in the study of liver diseases.

B. Kramer, J. Croswell, 2009, Journal of hepatology.

Statistical issues in randomized trials of cancer screening

P. Prorok, B. Kramer, S. Baker, 2002, BMC medical research methodology.

Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

E. Winer, B. Kramer, M. Kris, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

JNCI and cancer prevention.

B. Kramer, B. Dunn, Sharmistha Ghosh, 2015, Journal of the National Cancer Institute.

Multilevel modeling and value of information in clinical trial decision support

Bruce Tidor, Brendan Murphy, Paul M Coates, 2014, BMC Systems Biology.

Getting It Right: Being Smarter about Clinical Trials

Barnett S Kramer, Richard Hodes, B. Kramer, 2006, PLoS medicine.

Using relative utility curves to evaluate risk prediction

Nancy R Cook, Andrew Vickers, Stuart G Baker, 2009, Journal of the Royal Statistical Society. Series A,.

Cancer Prevention in the United States

B. Kramer, O. Brawley, 2013 .

Evaluating markers for the early detection of cancer: overview of study designs and methods

B. H. Patterson, B. Kramer, S. Skates, 2006, Clinical trials.

Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics.

Stuart G Baker, Barnett S Kramer, B. Kramer, 2008, Seminars in cancer biology.

Health screening needs independent regular re-evaluation

T. Wilt, L. Esserman, B. Kramer, 2021, BMJ.

Editorial: Challenges in Quantifying Overdiagnosis.

P. Prorok, B. Kramer, S. Baker, 2017, Journal of the National Cancer Institute.

American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction.

J. Cuzick, B. Kramer, P. Brown, 2009, Journal of oncology practice.

American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.

J. Cuzick, B. Kramer, P. Brown, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer screening: the clash of science and intuition.

B. Kramer, J. Croswell, 2009, Annual review of medicine.

Induced abortion, bias, and breast cancer: why epidemiology hasn't reached its limit.

B. Kramer, D. Weed, Barnett S. Kramer, 1996, Journal of the National Cancer Institute.

Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial.

J. Gohagan, B. Kramer, G. Andriole, 2006, Urology.

Early reporting for cancer screening trials

P. Prorok, B. Kramer, S. Baker, 2008, Journal of medical screening.

Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.

Laurence S Freedman, Stuart G Baker, Barnett S Kramer, 2005, Biostatistics.

Estimating the Cumulative Risk of a False‐Positive Test in a Repeated Screening Program

Barnett S Kramer, P. Prorok, B. Kramer, 2004, Biometrics.

Latent class instrumental variables: a clinical and biostatistical perspective

Stuart G Baker, Barnett S Kramer, B. Kramer, 2016, Statistics in medicine.

Repeat prostate biopsy in the Prostate, Lung, Colorectal and Ovarian cancer screening trial

J. Gohagan, B. Kramer, E. Crawford, 2007, BJU international.

The potential for hormonal prevention trials

B. Kramer, L. Ford, O. Brawley, 1994, Cancer.

RESEARCH HIGHLIGHTS: EBM from the Cochrane Library

T. Wilt, R. MacDonald, B. Kramer, 2009 .

Chemoprevention

B. Kramer, G. Kelloff, P. Greenwald, 2004 .

Chapter 2 – Cancer Screening and Prevention in the Older Patient

B. Kramer, J. Croswell, 2012 .

Reply to P.H. Frankel et al

B. Kramer, P. Schellhammer, M. Somerfield, 2009 .

Five-alpha-reductase Inhibitors for prostate cancer prevention.

T. Wilt, R. MacDonald, B. Kramer, 2008, The Cochrane database of systematic reviews.

Future Directions for Postdoctoral Training in Cancer Prevention: Insights from a Panel of Experts

Kara L. Hall, G. Colditz, B. Kramer, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening

P. Prorok, B. Kramer, S. Baker, 2003, BMC medical research methodology.

The bimanual ovarian palpation examination in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: Performance and complications

Barnett S Kramer, B. Kramer, P. Pinsky, 2017, Journal of medical screening.

Randomized trials, generalizability, and meta-analysis: Graphical insights for binary outcomes

B. Kramer, S. Baker, 2003, BMC medical research methodology.

Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial.

B. Kramer, C. Gatsonis, D. Aberle, 2016, The Lancet. Oncology.

The prostate, lung, colorectal, and ovarian cancer screening trial and its associated research resource.

J. Gohagan, P. Prorok, B. Kramer, 2013, Journal of the National Cancer Institute.

Lung cancer risk by years since quitting in 30+ pack year smokers

B. Kramer, P. Pinsky, Claire S Zhu, 2015, Journal of medical screening.

Study designs for determining and comparing sensitivities of disease screening tests

P. Prorok, B. Kramer, A. Miller, 2015, Journal of medical screening.

Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.

J. Gohagan, P. Prorok, B. Kramer, 2016, Gynecologic oncology.

The word “cancer”: how language can corrupt thought

Sudhir Srivastava, Barnett S Kramer, Barbara K Dunn, 2013, BMJ : British Medical Journal.

Biomedical research and dissemination: The value of global collaborations

Margarette E. Beckwith, B. Kramer, P. Hu, 2021, Journal of the National Cancer Center.

Lung Cancer Screening Websites-Balanced Information vs Advertisement.

B. Kramer, W. Black, S. Woloshin, 2020, JAMA internal medicine.

NIH Consensus 1994: screening.

P C Prorok, J. Gohagan, P. Prorok, 1994, Gynecologic oncology.

The Paired Availability Design for Historical Controls

Stuart G Baker, Barnett S Kramer, B. Kramer, 2001, BMC medical research methodology.

Thyroid incidentalomas in association with low-dose computed tomography in the National Lung Screening Trial.

B. Kramer, P. Pinsky, B. Dunn, 2019, American journal of epidemiology.

Screening for prostate cancer with PSA testing: current status and future directions.

B. Kramer, E. Crawford, J. Croswell, 2011, Oncology.

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Barnett S Kramer, John K Gohagan, J. Gohagan, 2005, The Journal of urology.

Overall and Multiphasic Findings of the Prostate, Lung, Colorectal and Ovarian (PLCO) Randomized Cancer Screening Trial.

J. Gohagan, P. Prorok, B. Kramer, 2018, Reviews on recent clinical trials.

Screening for Lung Cancer With Helical CT Scanning

J. Gohagan, P. Prorok, B. Kramer, 2002 .

Incidental renal tumours on low-dose CT lung cancer screening exams

B. Kramer, R. Munden, P. Pinsky, 2017, Journal of medical screening.

Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.

J. Gohagan, B. Kramer, E. Crawford, 2006, The Journal of urology.

Phase II evaluation of mitoxantrone in patients with bronchogenic carcinoma: a Southeastern Cancer Study Group trial.

B. Kramer, L. Einhorn, R. Buchanan, 1984, Cancer treatment reports.

Cancer overdiagnosis: a biological challenge and clinical dilemma

B. Kramer, A. D. De Marzo, A. Borowsky, 2019, Nature Reviews Cancer.

Cumulative false-positives (FP) in the prostate, lung, colorectal, ovarian (PLCO) cancer screening trial

J. Miller, J. Gohagan, P. Prorok, 2007 .

A population approach to precision medicine.

Muin J Khoury, Russell E Glasgow, Barnett S Kramer, 2012, American journal of preventive medicine.

Grappling with cancer--defeatism versus the reality of progress.

B. Kramer, B S Kramer, R D Klausner, 1997, The New England journal of medicine.

Early Detection Cancer Research Network

Sudhir Srivastava, Barnett S Kramer, B. Kramer, 2000, Laboratory Investigation.

Cumulative Incidence of False-Positive Test Results in Lung Cancer Screening

B. Kramer, J. Clapp, P. Marcus, 2010, Annals of Internal Medicine.

The PLCO Cancer Screening Trial: Background, Goals, Organization, Operations, Results.

J. Gohagan, P. Prorok, B. Kramer, 2015, Reviews on recent clinical trials.

Matching strength of message to strength of evidence: a discussion.

B. Kramer, 1999, Journal of the National Cancer Institute. Monographs.

Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.

B. Kramer, S. Baker, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cancer screening in theory and in practice.

B. Kramer, O. Brawley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conceptualizing overdiagnosis in cancer screening.

P. Prorok, B. Kramer, A. Miller, 2015, Journal of the National Cancer Institute.

Screening for prostate cancer: current status and future prospects.

B. Kramer, N. Sharifi, 2007, The American journal of medicine.

General keynote: cancer screening: translation of principles into practice.

B. Kramer, 2003, Gynecologic oncology.

Development Tracks for Cancer Prevention Markers

P. Prorok, B. Kramer, S. Baker, 2004, Disease markers.

Randomized trials for the real world: making as few and as reasonable assumptions as possible

Stuart G Baker, Barnett S Kramer, B. Kramer, 2008, Statistical methods in medical research.

Evaluating a new marker for risk prediction: decision analysis to the rescue.

Stuart G Baker, Barnett S Kramer, B. Kramer, 2012, Discovery medicine.

Breast cancer screening: toward informed decisions.

Joann G Elmore, Barnett S Kramer, J. Elmore, 2014, JAMA.

Short course prophylactic cranial irradiation for small cell lung cancer

J. Herman, B. Kramer, G. Clamon, 1985, American journal of clinical oncology.

Enhancement of fluorinated pyrimidine‐induced cytotoxicity by leucovorin in human lung cancer cell lines

B. Kramer, A. Gazdar, R. Perng, 1990, International Journal of Cancer.

Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial.

Paul Pinsky, Stuart G Baker, Barnett S Kramer, 2010, Biostatistics.

Clarifying the Role of Principal Stratification in the Paired Availability Design

B. Kramer, S. Baker, K. Lindeman, 2011, The international journal of biostatistics.